Table 2:

Trials of prasugrel and ticagrelor in acute coronary syndromes

Trial	Study population	Study groups	Outcome/adverse event	Intervention; % of patients		p value
				Prasugrel	Clopidogrel

TRITON– TIMI 38 ( 21 )	13 608 patients with acute coronary syndromes scheduled to have PCI	Prasugrel: 60-mg loading dose; 10 mg/d thereafter Clopidogrel: 300-mg loading dose; 75 mg/d thereafter	Cardiac death, MI or stroke (primary outcome)	9.9	12.1	< 0.0012

			Death, any cause	3.0	3.2	0.64

			Major bleeding	2.4	1.8	0.03

			Life-threatening bleeding	1.4	0.9	0.01

TRILOGY ACS ( 22 )	7 243 patients with unstable angina or acute coronary syndromes without ST-segment elevation without scheduled revascularization	Prasugrel: 30-mg loading dose; 10 mg/d thereafter (5 mg/d if age > 75 yr) Clopidogrel: 300-mg loading dose; 75 mg/d thereafter	Cardiac death, MI or stroke (primary outcome)	18.7	20.3	0.45

			Major bleeding	2.5	1.8	0.29

				Ticagrelor	Clopidogrel

PLATO ( 23 )	18 624 patients with acute coronary syndromes	Ticagrelor: 180-mg loading dose; 90 mg twice daily thereafter Clopidogrel: 300–600-mg loading dose; 75 mg/d thereafter	Death, MI or stroke (primary outcome)	9.8	11.7	< 0.001

			Death, any cause	4.0	5.1	0.001

			Stent thrombosis	2.9	3.8	0.01

			Major bleeding	11.6	11.2	0.43

			Bleeding unrelated to CABG	4.5	3.8	0.03

			Dyspnea	13.8	7.8	< 0.001

			Ventricular pauses > 3 s	5.8	3.6	0.01

				High-dose ASA	Low-dose ASA

CURRENT– OASIS 7 ( 13 )	25 086 patients with acute coronary syndromes scheduled to have PCI	High-dose ASA: 300–325 mg/d Low-dose ASA: 75–100 mg/d	Cardiac death, MI or stroke (primary outcome)	4.2	4.4	0.61

			Major bleeding	2.3	2.3	0.90

		Double-dose clopidogrel: 600-mg loading dose; then 150 mg/d for 6 d and 75 mg/d thereafter Standard-dose clopidogrel: 300-mg loading dose; 75 mg/d thereafter		Double-dose clopidogrel	Standard-dose clopidogrel

			Cardiac death, MI or stroke (primary outcome)	4.2	4.4	0.30

			Major bleeding	2.5	2.0	0.01

Note: ASA = acetylsalicylic acid, CABG = coronary artery bypass graft surgery, CURRENT–OASIS 7 = Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events–Seventh Organization to Assess Strategies in Ischemic Syndromes, MI = myocardial infarction, PCI = percutaneous coronary intervention, PLATO = Study of Platelet Inhibition and Patient Outcomes, TRILOGY ACS = Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes, TRITON–TIMI = Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction.